Innovative clinical trial design and delivery: a phase 3 COVID-19 post-exposure prophylaxis study in skilled nursing and assisted living facilities (BLAZE-2)

por Knorr, Jack, Tuttle, Jay L., Sabo, Janelle A., East, Dawn H., Price, Karen L., Shen, Lei
Publicado 2021

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis

por Dubinsky, Marla C, Jairath, Vipul, Feagan, Brian G, Naegeli, April N, Tuttle, Jay, Morris, Nathan, Shan, Mingyang, Arora, Vipin, Lissoos, Trevor, Agada, Noah, Hibi, Toshifumi, Sands, Bruce E
Publicado 2023

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study

por Steere, Boyd, Schmitz, Jochen, Powell, Nick, Higgs, Richard, Gottlieb, Klaus, Liu, Yushi, Jia, Bochao, Tuttle, Jay L., Sandborn, William J., Sands, Bruce E., D'Haens, Geert, Reinisch, Walter, Krishnan, Venkatesh
Publicado 2023

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

por Vadhan-Raj, Saroj, Abonour, Rafat, Goldman, Jonathan W., Smith, David A., Slapak, Christopher A., Ilaria, Robert L., Tiu, Ramon V., Wang, Xuejing, Callies, Sophie, Cox, Joanne, Tuttle, Jay L., Lau, Yiu-Keung, Roeland, Eric J.
Publicado 2017

The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination

por Benschop, Robert J., Tuttle, Jay L., Zhang, Lin, Poorbaugh, Josh, Kallewaard, Nicole L., Vaillancourt, Peter, Crisp, Melissa, Trinh, Thi Ngoc Vy, Freitas, Joshua J., Beasley, Stephanie, Daniels, Montanea, Haustrup, Natalie, Higgs, Richard E., Nirula, Ajay, Cohen, Myron S., Marovich, Mary
Publicado 2022